Over-the-Counter Human Drugs; Labeling Requirements

ICR 201312-0910-009

OMB: 0910-0340

Federal Form Document

Forms and Documents
Document
Name
Status
Supporting Statement A
2013-12-17
ICR Details
0910-0340 201312-0910-009
Historical Active 201008-0910-009
HHS/FDA 21080
Over-the-Counter Human Drugs; Labeling Requirements
Extension without change of a currently approved collection   No
Regular
Approved without change 01/27/2014
Retrieve Notice of Action (NOA) 12/20/2013
  Inventory as of this Action Requested Previously Approved
01/31/2017 36 Months From Approved 01/31/2014
961 0 5,650
11,523 0 14,303
2,100,000 0 3,663,000

Regulations established in March 1999 (21 CFR 206.66) define format and content requirements for the labeling of over-the-counter (OTC)drug products. Specifically, these requirements apply to labeling within the Drug Facts panel required for all OTC drug products (i.e., "Drug Facts" labeling). All OTC drug products except sunscreens have been required to comply with the labeling requirements set forth in 21 CFR 206.66 since June 2005. Complying with these regulations imposes a burden on the manufacturers of new OTC drug products. The burden consists of preparing new labeling for these products that complies with the Drug Facts labeling requirements

US Code: 21 USC 201, 502, 503, 505, and 701 Name of Law: Federal Food, Drug, and Cosmetics Act
  
None

Not associated with rulemaking

  78 FR 44124 07/23/2013
78 FR 73197 12/05/2013
Yes

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 961 5,650 0 0 -4,689 0
Annual Time Burden (Hours) 11,523 14,303 0 0 -2,780 0
Annual Cost Burden (Dollars) 2,100,000 3,663,000 0 0 -1,563,000 0
No
No
The previous burden estimate in 2011 was 14,303 hours. The decrease in burden to 11,523 (-2,780) hours is mostly attributed to a decrease in the number of manufacturers of sunscreen drug products and a corresponding decrease in the number of total annual burden for manufacturers of new products marketed under NDA, ANDAs, or OTC drug monographs used for the estimates under section 201.66(c) and (d). In addition, the respondents of sunscreen drug products has decreased from the estimate in 2011 from 400 to 20. Conversely, the hours per response increased from 9500 to 720.

$0
No
No
No
No
No
Uncollected
ILa Mizrachi 301 796-7726 [email protected]

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
12/20/2013


© 2024 OMB.report | Privacy Policy